Incretin

The Incretin Impact: A New Era in Metabolic Disease and Obesity Drug Development, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, April 16, 2024
University, Incretin, DSM-IV codes, All India Mahila Congress, Diabetes, PET, Entrepreneurship, Drug discovery, Obesity, University of Copenhagen, Senior, Magnetic resonance imaging, MRI, Drug development, Chemistry, Gelastic seizure

TORONTO , April 16, 2024 /PRNewswire-PRWeb/ -- With the demonstrated efficacy and approvals of recent incretin-based therapies for the treatment of diabetes and obesity, one might think this is it for incretins. But really, it is just the beginning — given the possibilities for new combinations, different formulations and more indications throughout metabolic diseases and beyond.

Key Points: 
  • Attendees will learn why the future of incretin drug development will likely expand with different combinations, formulations and disease indications.
  • It is currently a very exciting time within drug development for incretins, but there is still a lot we do not know.
  • How can we better understand their effects and advance drug development in obesity and metabolic disease?
  • Register for this webinar today to learn about incretins, the current status of incretin drug development and the speakers' perspectives on the future of incretin drug development.

BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

Retrieved on: 
Tuesday, April 9, 2024
Research, FDA, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Internal medicine, Incretin, Obesity, AstraZeneca, Novo Nordisk, Cardiology, University college, Patient, DSM-IV codes, Weight loss, NAMS, Doctor of Philosophy, MD, Biology, PPD, Inc., Book, Ageing, Pharmaceutical industry

BioAge Labs, Inc., ("BioAge"), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, today announced the appointment of Michael Davidson, MD to the company's board of directors.

Key Points: 
  • BioAge Labs, Inc., ("BioAge"), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, today announced the appointment of Michael Davidson, MD to the company's board of directors.
  • "We are delighted to welcome Michael to BioAge's board of directors," said Kristen Fortney, PhD, CEO and co-founder of BioAge Labs.
  • "I'm excited to join the board of BioAge at this pivotal juncture, as the company progresses azelaprag into Phase 2 trials in obesity," said Davidson.
  • I look forward to working with the team to bring this promising therapy to patients in need."

Svetlana Mojsov named 2024 recipient of the Pearl Meister Greengard Prize

Retrieved on: 
Wednesday, February 28, 2024
Glucagon, Diabetes, Rockefeller's, Woman, Pearl Meister Greengard Prize, Rockefeller University, Dicarboxylic acid, Obesity, Incretin, Vincent Astor, Zookeeper, Insulin, Pancreas, Massachusetts General Hospital, Research, Nobel Prize, Partnership, Pharmaceutical industry

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Svetlana Mojsov , whose research into hormonal triggers for insulin production led to groundbreaking treatments for diabetes and obesity, will receive the 2024 Pearl Meister Greengard Prize, The Rockefeller University announced today.

Key Points: 
  • NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Svetlana Mojsov , whose research into hormonal triggers for insulin production led to groundbreaking treatments for diabetes and obesity, will receive the 2024 Pearl Meister Greengard Prize, The Rockefeller University announced today.
  • Mojsov, a research associate professor at Rockefeller, will be honored at a ceremony on campus on April 17.
  • The Pearl Meister Greengard Prize was established by the late Paul Greengard , the Vincent Astor Professor at Rockefeller, and his wife, the sculptor Ursula von Rydingsvard.
  • Visit this page to register for the Pearl Meister Greengard Prize ceremony and learn more about the award.

BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics

Retrieved on: 
Tuesday, February 13, 2024
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Therapy, OrbiMed, Body composition, Obesity, Incretin, Ageing, Weight loss, Venture round, Doctor of Philosophy, DSM-IV codes, Pivotal, Biology, Muscle atrophy, Investment, Pharmaceutical industry

BioAge Labs (“BioAge”), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, announced today the completion of an oversubscribed Series D financing round of $170 million led by Sofinnova Investments.

Key Points: 
  • BioAge Labs (“BioAge”), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, announced today the completion of an oversubscribed Series D financing round of $170 million led by Sofinnova Investments.
  • In connection with the financing, James Healy, M.D., Ph.D., managing partner at Sofinnova Investments, will join BioAge as Chairman of the Board, and Patrick Enright, managing director at Longitude Capital, will join as Board Director.
  • In preclinical studies, azelaprag doubled the weight loss achieved on incretin drugs with improvements in body composition and muscle function.
  • “We’re thrilled to partner with a top-tier syndicate of investors and pharma companies at the forefront of developing novel therapeutics for metabolic diseases,” said Kristen Fortney, Ph.D., CEO and co-founder of BioAge.

Carmot Therapeutics Announces Completion of Acquisition by Roche

Retrieved on: 
Monday, January 29, 2024
Diabetes, Obesity, DSM-IV codes, Patient, Weight loss, Acquisition, Therapy, Incretin, Overweight, Metabolism, Pharmaceutical industry

BERKELEY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Carmot Therapeutics Inc. (Carmot), a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, today announced that its acquisition by the Roche Group (Roche) has been completed.

Key Points: 
  • BERKELEY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Carmot Therapeutics Inc. (Carmot), a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, today announced that its acquisition by the Roche Group (Roche) has been completed.
  • Having successfully completed its acquisition of Carmot, Roche obtains access to Carmot’s current R&D portfolio including all clinical and pre-clinical assets, as well as exclusive access to Carmot’s innovative Chemotype Evolution discovery platform in metabolism, further strengthening Roche’s R&D efforts and portfolio across cardiovascular and metabolic diseases.
  • Carmot and its employees will join the Roche Group as part of Roche’s Pharmaceuticals Division.
  • Roche has acquired all outstanding shares and options of Carmot at a purchase price of $2.7 billion.

Perpetual Medicines Completes $8 Million Seed Round to Advance Integrated Computational Design-Synthesis Platform for Peptide Drug Discovery

Retrieved on: 
Friday, December 1, 2023
Oncology, Health, Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, Intarsia, Initial public offering, Amylin Pharmaceuticals, GSK plc, Vancomycin, Senior, Head, Protein, APS, Artificial intelligence, Machine learning, Medication, Eli Lilly, Therapy, Perpetual, Eli Lilly and Company, MD, Harvard Medical School, Deep learning, Drug discovery, Drug development, Spotlight Innovation, Doctor of Philosophy, Incretin, Autoimmunity, Fine chemical, Management, Chemistry

Perpetual Medicines today announced it has closed an $8 million seed financing to advance its integrated computational design and synthesis platform for peptide drug discovery.

Key Points: 
  • Perpetual Medicines today announced it has closed an $8 million seed financing to advance its integrated computational design and synthesis platform for peptide drug discovery.
  • “Perpetual Medicines is capitalizing on recent advances in computational modeling based on artificial intelligence, deep learning and machine learning that enable access for the first time to the enormous, untapped peptide chemical space for drug discovery,” said Dr. Blanchard.
  • This approach has the potential to accelerate peptide drug discovery, reduce cost, and increase the quality of drug candidates.
  • Ved Srivastava, PhD, Chief Technology Officer – Dr. Srivastava brings to Perpetual Medicines more than 25 years of experience in the discovery and development of peptide therapeutics.

BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class Apelin Receptor Agonist BGE-105/Azelaprag Co-Administered With Tirzepatide for Treatment of Obesity, in Collaboration With Lilly’s Chorus Organization

Retrieved on: 
Thursday, October 26, 2023
Health, Fitness & Nutrition, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Science, Lilly, Eli Lilly and Company, Ageing, Concept, Biomarker, Therapy, Heart, Obesity, Weight loss, Apelin, Doctor of Philosophy, Agonal respiration, Maintenance, Exercise, Metabolism, Drug development, Incretin, Muscle atrophy, Biology, Amgen, Bed rest, Chemistry, Central nervous system, Pharmaceutical industry, Dietary supplement, Chorus

As part of the collaboration, Lilly will also provide BioAge with tirzepatide.

Key Points: 
  • As part of the collaboration, Lilly will also provide BioAge with tirzepatide.
  • “We are thrilled to work directly with the clinical development experts at Chorus and benefit from Lilly’s expertise in obesity drug development,” said Kristen Fortney, PhD, CEO and co-founder of BioAge.
  • “Our Phase 2 trial is designed to assess whether azelaprag can substantially increase the weight loss achieved with drugs of the incretin class.
  • Apelin signaling has demonstrated multiple benefits in energy metabolism in mouse models, including increased insulin sensitivity and reduction in fat mass.

Versanis Announces Initiation of the BELIEVE Global Phase 2b Study of Bimagrumab as a Novel Treatment for Obesity

Retrieved on: 
Thursday, January 12, 2023
Bimagrumab, Type 2 diabetes, Incretin, Safety, Weight loss, Overweight, Therapy, Patient, Muscle, Obesity, Weight, Pharmaceutical industry

NEW YORK, Jan. 12, 2023 /PRNewswire/ -- Versanis Bio ("Versanis"), a clinical-stage biopharmaceutical company advancing novel therapeutics for cardiometabolic diseases, today announced that the BELIEVE Phase 2b study to assess the safety and efficacy of bimagrumab alone and in combination with semaglutide for the treatment of obesity has begun enrolling at sites in the U.S., Australia, and New Zealand.

Key Points: 
  • It is the only candidate in clinical development for the treatment of obesity that drives substantial fat loss while also increasing muscle mass.
  • "We are thrilled with the enthusiasm for the study and have already enrolled close to 20% of our targeted patients."
  • BELIEVE is a randomized, placebo-controlled, 48-week global Phase 2b study targeting enrollment of 450 non-diabetic patients with overweight or obesity who will receive placebo or bimagrumab, with or without semaglutide.
  • The study will assess the safety and efficacy of bimagrumab both as a monotherapy and when co-administered with semaglutide.

Versanis Presents Preclinical Data Demonstrating the Potential of Bimagrumab as a Novel Obesity Treatment at ObesityWeek 2022

Retrieved on: 
Wednesday, November 2, 2022
Atlas Venture, Waist, Weakness, Mouse, Bimagrumab, Myostatin, Incretin, Obesity, Ligand, Body composition, Safety, GDF11, Activin and inhibin, Atlas, Human, Muscle, Patient, Multimedia, Therapy, Pharmaceutical industry, Dietary supplement

NEW YORK, Nov. 2, 2022 /PRNewswire/ -- Versanis Bio ("Versanis"), a clinical-stage biopharmaceutical company advancing novel therapeutics for cardiometabolic diseases, today shares new preclinical data reaffirming the potential of lead asset bimagrumab as a novel obesity treatment at ObesityWeek 2022, hosted November 1-4 in San Diego. The new preclinical results highlight the therapeutic potential of bimagrumab as a monotherapy and also when co-administered with incretin therapies in people living with obesity.

Key Points: 
  • NEW YORK, Nov. 2, 2022 /PRNewswire/ --Versanis Bio ("Versanis"), a clinical-stage biopharmaceuticalcompany advancing novel therapeutics for cardiometabolic diseases, today shares new preclinical data reaffirming the potential of lead asset bimagrumab as a novel obesity treatment at ObesityWeek 2022, hosted November 1-4 in San Diego.
  • The new preclinical results highlight the therapeutic potential of bimagrumab as a monotherapy and also when co-administered with incretin therapies in people living with obesity.
  • Experiments in a diet-induced obesity model in mice showed that the mouse version of bimagrumab elicited fat mass loss and lean mass gain.
  • "These data reported today at ObesityWeek contribute to the growing body of preclinical and clinical data that support our upcoming Phase 2b study of bimagrumab in patients living with obesity."

Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)

Retrieved on: 
Wednesday, September 21, 2022
Fatty liver disease, Safety, COVID-19, Advertising, MD, Vomiting, NASH, Week, Overweight, GCG, Obesity, Intellectual property, Private Securities Litigation Reform Act, Metformin, Glucagon, Patient, BI, 2021 Essex County Council election, Abstract, Nasdaq, Liver, Science, Pharmacology, European Association for the Study of Diabetes, GCGR, Research, EASD, Boehringer Ingelheim, Association, Nausea, Boehringer, Incretin, T2D, Failure, Human, Fine chemical, Pharmaceutical industry, Vaccine, Glycated hemoglobin, Zealand Pharma

Preclinical data on BI 456906 will also be presented at the EASD annual meeting.

Key Points: 
  • Preclinical data on BI 456906 will also be presented at the EASD annual meeting.
  • BI 456906 is being developed by Boehringer Ingelheim and was co-invented with Zealand Pharma.
  • Most adverse events were reported during the dose-escalation phase of the trial, and therefore slower escalation schemes may mitigate the frequency.
  • Different doses of BI 456906 were escalated every 12 weeks to ensure that 10 weeks were spent on a maintenance dose.